David McCall, Senior Editor, BioInsights, speaks to Gopi Shanker, Chief Scientific Officer, Beam Therapeutics, about the company’s mission to realize the full potential of base editing for patient treatment. They discuss the stand-out advantages of base editing, as well as the current state of the art in the area of multiplex gene editing.
